IPO

With a novel 'gastric bypass in a pill' and a new CFO known for orchestrating lucrative exits, Syntis Bio is gearing up for a high-stakes battle in the booming obesity drug market.

With a Halliburton deal and $70M in hand, Greenland Energy is chasing a 13-billion-barrel prize. It's a high-risk play pitting economic hope against Arctic fragility.

By adding a public company CFO and a veteran tech investor, AI chipmaker Syntiant is laying the groundwork for aggressive scaling and a potential public offering.

Eikon Therapeutics adds a consumer goods giant to its board, a move signaling a strategic pivot from pure science to global commercialization.

With expanded coverage for 52 million Americans, Tonix Pharmaceuticals' TONMYA® is not just a drug launch; it's a market disruption for chronic pain.

A landmark study validates Ceribell's AI in predicting neurological outcomes, signaling a major shift in critical care and bolstering its competitive edge.

With $173 million pouring into its tokenized SpaceX offering, MEXC is blurring the lines between crypto and Wall Street. But are retail investors buying a ticket to the moon or just a reflection of the rocket?

Set to join the Russell 3000, Starfighters Space and its unique F-104 fleet bring Wall Street's focus to a new class of aerospace infrastructure.

Sunshine Silver's successful IPO is more than a financial event; it's a high-stakes bet on reviving a storied mine and securing America's silver supply.

SpaceX's record-shattering $75 billion IPO promises unprecedented access for retail investors, but a sky-high valuation and governance red flags loom large.

With a fresh $287.5M, Keystone Acquisition Corp. is targeting US industrial innovation. But can it find a winner in 2026's competitive SPAC market?

The successful Hong Kong IPO of a LanzaTech joint venture isn't just a financial win; it's a market validation for turning pollution into valuable products.

NASDAQ's Eightco is selling a dream: single-stock access to AI's giants and the future of identity. But is it a visionary bet or a high-risk house of cards?

MEXC's 'RealStocks' offers direct U.S. equity ownership on its crypto platform. But does this fusion of TradFi and Web3 live up to the hype?

The Motherhood Choice Awards are more than a ceremony. They are the public face of a complex digital ecosystem designed to guide Malaysian parents through a maze of choices.

Freshly independent, MiniMed reports record sales and a robust product pipeline, signaling a focused strategy to dominate the competitive diabetes tech market.

Amazon's historic rise to No. 1 on the Fortune 500 signals a definitive power shift, crowning the digital economy over traditional American business.

Fresh off its IPO, Bill Ackman's firm is ditching the exclusive call for open X Spaces Q&As. A signal of radical transparency or a new compliance risk?

As SpaceX targets a historic IPO, its rockets are overshadowed. Starlink's satellite internet is now the sole profit engine, forcing a radical re-evaluation.

With a $1.25 billion investment from Apollo Funds, McKesson is spinning off its medical supply unit. Is this a cure for corporate bloat or a new symptom of financialization in healthcare?